11 Results

People

  1. Danila
    Danila
  2. Scher
    Scher
  3. Fleisher
    Fleisher
  4. Schreiber
    Schreiber
  5. Herkal
    Herkal
  6. Bambury
    Bambury
  7. Heller
    Heller
  8. Patel
    Patel
  9. Anand
    Anand
  10. Bastos
    Bastos

Groups

  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Biostatistics Service (4)
  5. Epidemiology and Biostatistics (4)
  6. Molecular Imaging and Therapy Service (3)
  7. Radiology, Department of (1)
  1. "Nicole Schreiber"
  2. "Howard Scher"
  3. "Daniel Danila"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Biostatistics Service (4)
  5. Epidemiology and Biostatistics (4)
  6. Molecular Imaging and Therapy Service (3)

More Groups

People
  1. Daniel Danila (11)
  2. Howard Scher (11)
  3. Nicole Schreiber (11)
  4. Martin Fleisher (9)
  5. Amrita Herkal (5)
  6. Chintan Patel (4)

More People

Years
  1. 2017 (1)
  2. 2016 (3)
  3. 2015 (4)
  4. 2014 (1)
  5. 2013 (2)
Publications
  1. Journal of Clinical Oncology (5)
  2. Annals of Oncology (1)
  3. Cancer Research (1)
  4. European Urology (1)
  5. JAMA Oncology (1)
  6. Journal of Molecular Diagnostics (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Science, Inc. (2)
  3. American Association for Cancer Research (1)
  4. American Medical Association (1)
  5. Lippincott Williams & Wilkins (1)
  6. Oxford University Press (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients
    Journal Article

    Danila, D. C.; Samoila, A.; Patel, C.; Schreiber, N.; Herkal, A.; Anand, A.; Bastos, D.; Heller, G.; Fleisher, M.; Scher, H. I.
    The Cancer Journal (2016)

    Fulltext@MSK | Save
  • Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Scher, H. I.; Szafer-Glusman, E.; Herkal, A.; Suttmann, R.; Fleisher, M.; Schreiber, N. A.; Curtis, K.; Gilbert, H.; Maslyar, D.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC)
    Meeting Abstract

    Landers, M.; Greene, S.; Schreiber, N. A.; Rodriguez, A.; Bambury, R. M.; Danila, D. C.; Rathkopf, D. E.; Fleisher, M.; Louw, J.; Jendrisak, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Danila, D. C.; Fleisher, M.; Carrasquillo, J. A.; Gilbert, H.; Morris, M. J.; Bellomo, L. P.; Hendrikx, P. J.; Szafer-Glusman, E.; Herkal, A.; Patel, C.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Louw, J.; Jendrisak, A.; Bambury, R. M.; Danila, D. C.; Rathkopf, D. E.; Arslan, Z.; Schreiber, N. A.; Lu, D.; Krupa, R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Dittamore, R.; Louw, J.; Krupa, R.; Danila, D. C.; Arslan, Z.; Schreiber, N. A.; Bales, N.; Marrinucci, D.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A pilot study comparing circulation tumor cells (CTC) detection by AdnaTest prostate assay to CellSearch in patients (pts) with castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Samoila, A.; Bastos, D. A.; Herkal, A.; Patel, C.; Curtis, K. R.; Schreiber, N. A.; Anand, A.; Fleisher, M.; Scher, H. I.; Danila, D. C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save